Онбрез Бризхалер

Quick links

Choose a section

Quick links to important sections

Advertisements

Онбрез Бризхалер

Selected form

Advertisements
Advertisements
Advertisements

Overview of Онбрез Бризхалер

Quick Facts

Property Description
Active Ingredient Indacaterol maleate
Form Inhalation Powder, Hard Capsules
Pharmacological Class Ultra-Long-Acting beta2-Adrenergic Agonist (ULABA)
Common Use Maintenance bronchodilator treatment for chronic airflow obstruction
Origin Synthetic Compound

What Class of Medication Does Onbrez Breezhaler Belong To?

Onbrez Breezhaler is a prescription-only pharmaceutical product classified as an ultra-long-acting beta2-adrenergic agonist (LABA), which functions to achieve bronchodilation. Its active substance is Indacaterol maleate, a synthetic compound. The drug is designated for the long-term, once-daily maintenance treatment of persistent airflow obstruction in adult patients. Supported by pharmacological studies, this formulation is clinically recognized for its extended duration of action, ensuring continuous therapeutic benefit throughout the day.

What is the Dosage Form and Composition?

The medication is supplied as an inhalation powder contained within hard capsules, which must be administered only via the dedicated Breezhaler inhaler device. The capsules are intended exclusively for oral inhalation and must not be swallowed, a key instructional difference from oral medications. This formulation is a single-active-ingredient product, featuring Indacaterol maleate alongside the excipient, Lactose monohydrate. The proprietary Breezhaler device facilitates the targeted delivery of the inhalation powder directly into the airways.

What is the Primary Purpose of Using Onbrez Breezhaler?

The primary purpose of Onbrez Breezhaler is to provide continuous, 24-hour relief by relaxing the air passages and maintaining open airways. Indacaterol’s physiological action is to promote the relaxation of the bronchial smooth muscle, resulting in bronchodilation. This sustained opening of the airways is a critical benefit for managing chronic conditions, allowing patients to experience improved flow of air and reduced sensation of tightness with the convenience of once-daily administration.

Advertisements

What side effects are possible with Онбрез Бризхалер?

Possible Side Effects and Safety Information

This section outlines the adverse reactions and safety characteristics for Indacaterol maleate as officially documented in government regulatory labeling. The information is presented without clinical advice or instruction.


Adverse Reaction Scope

Category Official Regulatory Statement
Frequency classification Very Common: Upper respiratory tract infection, Nasopharyngitis. Common: Headache, Cough, Oropharyngeal pain (including throat irritation), Ischaemic heart disease, Hyperglycaemia, Palpitations, Muscle spasm, Peripheral oedema. Uncommon: Paradoxical bronchospasm, Tachycardia, Atrial fibrillation, Dizziness, Hypersensitivity reactions (e.g., angioedema), Dry mouth, Insomnia.
System-organ classes involved Infections and Infestations, Metabolism and Nutrition Disorders, Nervous System Disorders, Cardiac Disorders, Immune System Disorders, Respiratory/Thoracic/Mediastinal Disorders, Musculoskeletal and Connective Tissue Disorders.
Serious adverse reactions Paradoxical Bronchospasm can be life-threatening and necessitates immediate discontinuation. Immediate Hypersensitivity Reactions (e.g., angioedema) have been documented. Cardiovascular Effects such as Tachycardia, Atrial fibrillation, and Ischaemic heart disease are officially listed in the safety profile.
Population-specific safety Safety in patients with Severe Hepatic Impairment is not established due to limited clinical data. No specific dose adjustment is generally required for patients with Renal Impairment or Older Adults.
Safety-related limitations The medicine is strictly for long-term maintenance treatment and must not be used to treat acute, sudden episodes of bronchospasm. The label defines the need for evaluation if the patient's underlying condition rapidly deteriorates.

Safety Classifications (High-Level)

Category Official Regulatory Statement
Regulatory basis Official safety information is derived from government documents like the Summary of Product Characteristics (SmPC) approved by the European Medicines Agency (EMA) and the Prescribing Information approved by the U.S. Food and Drug Administration (FDA).
Context-of-use safety notes The drug, like other beta2-adrenergic agonists, may produce clinically significant effects such as Hypokalaemia (low potassium) and Hyperglycaemia (high blood glucose), which are recognized as class effects.

Connection to the Overall Safety Profile

This officially documented profile, organized by frequency and organ system, details the systemic and localized effects inherent to the Ultra-Long-Acting beta2-Agonist class. By explicitly identifying serious adverse reactions and outlining restrictions on use (such as for acute symptoms), regulatory information provides a factual basis for understanding the non-therapeutic risks. Specific constraints regarding severe hepatic impairment further define the boundaries of the drug’s established regulatory safety profile.

Advertisements

Overdose and Emergency Response

Overdose of Онбрез Бризхалер is associated with manifestations of excessive beta-adrenergic stimulation, as documented in regulatory information. These signs reflect the drug’s pharmacological action and include: fast, pounding, or irregular heartbeat, chest pain, shaking of a part of the body (tremor), nervousness, headache, dizziness, dry mouth, nausea, and muscle cramps.

Excessive use of this medication or its drug class (Long-Acting beta2-Adrenergic Agonists) can lead to clinically significant cardiovascular effects, and the official labeling indicates that this excessive use may be fatal. Additionally, an overdose is associated with the potential for metabolic abnormalities, specifically hypokalemia (low serum potassium) and hyperglycemia (high blood sugar).

Regulators mandate specific emergency actions in case of a suspected overdose. It is required to immediately contact a poison control helpline or a healthcare professional, even if symptoms are not immediately present. Urgent medical help must be sought by immediately calling emergency services if the victim has collapsed, is experiencing a seizure, has severe trouble breathing, or cannot be awakened. Management of overdose in a clinical setting is described as symptomatic and supportive treatment.

Advertisements

Therapeutic Uses of Онбрез Бризхалер

What Онбрез Бризхалер Treats: Main Uses and Benefits

This medication is considered relevant for managing the symptoms associated with chronic obstructive pulmonary disease (COPD). It is primarily applied in situations involving continuous symptomatic support for persistent airflow obstruction in adult patients, encompassing conditions such as chronic bronchitis and emphysema.


Therapeutic Role and Symptom Relief

The medicine is applied in addressing symptom clusters that create noticeable physiological strain, which typically manifest as chronic shortness of breath, persistent wheezing, and a sensation of chest tightness. It helps provide continuous symptomatic support, which contributes to improved comfort during periods of heightened symptoms and may assist with maintaining functional stability.

Its consistent action supports a patient's functional breathing capacity, helping patients cope more steadily with the breathing difficulties experienced during routine activities, supporting general well-being during symptomatic phases.

Quick Fact: Relief for Persistent Discomfort
Primary Indication Maintenance treatment for Chronic Obstructive Pulmonary Disease (COPD).
Key Symptoms Addressed Persistent shortness of breath, wheezing, and chest tightness.
Benefit Focus Continuous symptomatic support and maintenance of day-to-day comfort.

Regulatory References

  1. European Medicines Agency overview
Advertisements

Eligibility and Restrictions for Use

Eligibility Scope

Category Eligibility Rule (Strictly Regulatory Text)
Populations Allowed Adult patients (18 years and older) diagnosed with Chronic Obstructive Pulmonary Disease (COPD) for maintenance treatment.
Populations Contraindicated Patients with known hypersensitivity to indacaterol or any component (e.g., lactose); those with asthma; or for treating acute bronchospasm (not a rescue inhaler).
Age-Related Rules Pediatric use (under 18 years) is not recommended as safety and efficacy have not been established. Older adults require no dose adjustment.
Organ Function Rules No dose adjustment is required for renal impairment or mild/moderate hepatic impairment. Use in severe hepatic impairment is not established due to insufficient data.
Reproductive Status Pregnancy: Not recommended unless benefits outweigh risks. Lactation: A decision must be made to discontinue nursing or discontinue the drug.

Eligibility Classifications (High-Level)

Classification Regulatory Basis Eligibility Context Constraints
Allowed EMA, FDA, Health Canada Maintenance treatment only; must be ge 18 years old.
Contraindicated EMA, FDA Hypersensitivity, Acute Bronchospasm relief, Asthma (use alone).
Limited/Caution EMA, FDA Severe Hepatic Impairment, Severe Cardiovascular Disorders, Thyrotoxicosis.

Official Eligibility Statements

  • The medicine is indicated solely for maintenance bronchodilator treatment of airflow obstruction in adult patients with COPD.
  • It is contraindicated in patients with hypersensitivity to indacaterol or excipients, and is not indicated for use in asthma.
  • Use in the pediatric population (under 18 years) is not recommended due to lack of established safety and efficacy.
  • Use requires caution in patients with certain severe cardiovascular disorders and metabolic conditions such as diabetes mellitus.

The regulatory documents clearly define that only adults with COPD are the approved population for the medicine’s maintenance use, establishing absolute exclusions for hypersensitivity, asthma, and acute symptom relief, and setting conditional use requirements for specific groups with co-morbidities.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines interaction patterns documented in official regulatory sources for Indacaterol maleate.

Formal Interaction Restrictions

Co-administration with other Long-Acting beta2-Adrenergic Agonists (LABA) is prohibited due to the risk of excessive beta-adrenergic stimulation. Concomitant use with beta-Adrenergic Blockers (including eye drops) is generally not recommended as it may cause pharmacodynamic antagonism, weakening the bronchodilator effect.

Pharmacokinetic and Pharmacodynamic Interactions

  • Exposure-Altering Interactions: The clearance of Indacaterol is reduced by dual inhibitors of the CYP3A4 enzyme and the P-glycoprotein (P-gp) transporter, such as ketoconazole. This interaction leads to an increase in systemic exposure, though regulatory documents state this increase does not raise safety concerns at the maximum recommended dose.
  • Cardiovascular Potentiation: Caution is advised when co-administering with Monoamine Oxidase (MAO) Inhibitors, Tricyclic Antidepressants, and drugs that prolong the QTc interval, as these may potentiate cardiovascular effects.
  • Hypokalemia Risk: Co-administration with Xanthine Derivatives, Steroids, and Non-Potassium Sparing Diuretics may potentiate the risk of low potassium levels (hypokalemia) or cause related ECG changes.

Other Considerations

The formulation contains lactose, which includes milk proteins; therefore, use is cautioned in patients with a history of severe milk protein allergy. No specific mandatory time separation between doses or interactions with alcohol or general herbal products are documented in official regulatory labeling.

Advertisements

Mechanism of Action

Targeted beta2-Adrenergic Receptor Engagement

Онбрез Бризхалер (Indacaterol) initiates its effect by acting as a selective agonist on the mathbfbeta2 -adrenergic receptors located on the smooth muscle of the airways . Binding to this target activates an intracellular cascade, classifying its function within the mechanistic domain of receptor-mediated signaling that governs muscle tone. This initial engagement is the core step that modifies early molecular signaling events, which subsequently leads to the relaxation of the bronchial smooth muscles.

Modulation of Intracellular Signaling Pathways

The activation of the beta2-receptors leads to the modulation of the cAMP-dependent signal transduction pathway. This involves activating the enzyme adenylyl cyclase, which increases the level of the second messenger cyclic AMP (cAMP) within the cell. The increased cAMP activity modifies the function of contractile processes and causes a reduction in the effect of contractile mediators, ultimately resulting in the key physiological consequence of bronchodilation.

Sustained Mechanistic Activity Pattern

The drug exhibits a prolonged binding interaction and a unique partitioning behavior (lipophilicity) that sustains the stimulation of the beta2-AR over an extended period. This sustained mechanistic activity ensures a continuous engagement with the target pathway, sustaining the shift toward a relaxed state within the bronchial pathways and resulting in prolonged physiological modulation of airway function.

Advertisements

Dosage and Administration Information

Official Administration Guidelines and Dosage

Онбрез Бризхалер is a medication designated for long-term maintenance treatment of persistent airflow obstruction. Its use is defined by standardized dosing and proper administration patterns.

Route, Device, and Preparation

Administration must be performed solely via oral inhalation using the dedicated Breezhaler device. The capsule containing the inhalation powder is designed to be inhaled and must not be swallowed. The proper procedure requires that the capsule be removed from its blister packaging immediately prior to use to protect the integrity of the powder from moisture.

Dosing Schedule and Frequency

The established regimen is once daily (o.d.), and the dose should be administered at the same time each day to ensure continuous therapeutic coverage. The standard adult maintenance dose involves inhaling the contents of one 150 microgram (mcg) capsule. The maximum recommended daily dose is 300 mcg, which may be used for patients who require additional clinical benefit.

Special Usage Instructions

No dose adjustment is required for older adults (geriatric patients) or for those with mild to moderate renal or hepatic impairment. The medicine is not recommended for use in patients under 18 years of age. If a dose is missed, the patient should inhale the next dose at the usual time the following day, and a double dose must never be taken to compensate for the forgotten dose. The adherence to this continuous, fixed-schedule protocol defines the correct use of the medicine.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies

Research has explored whether this treatment is associated with findings measured in the study, and studies evaluated whether there were measured differences in participant-reported quality of life. Some studies included comparisons with older methods, and the studies reported varying results.


Study Design: Biological Markers and Time-Related Measures

Studies examined whether the drug was associated with changes in inflammatory markers, and research evaluated the time-to-onset of reported symptom changes. Clinical trials found that the bronchodilating effect often occurred rapidly, typically within minutes of the first dose, and lasted for 24 hours.


Dosing and Treatment Duration

Research examined the dose and duration of administration in study populations to evaluate the measurements of participant-reported pain levels over the course of the study. Pooled data from multiple clinical trials spanning up to one year have been analyzed to assess the long-term impact on lung function and symptoms.


Combination Therapy Research

Research has evaluated whether the use of the combination was associated with specific measured results and whether differences were measured in the occurrence of specific events between groups. Evidence remains limited regarding the long-term measurements associated with combination approaches. Studies involving indacaterol in combination with other bronchodilators have shown greater improvements in lung function and other patient-reported outcomes compared to monotherapy.


Study Design: Tolerability and Adverse Events

Studies have evaluated the tolerability of the treatment in people with various pre-existing conditions. Findings identified specific populations or conditions where participants reported differences in adverse event rates. The most commonly reported adverse events in clinical trials were generally mild to moderate, including nasopharyngitis, upper respiratory tract infection, and cough.

Key Studies & References

  1. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD (Comparison of efficacy and symptom improvement over 52 weeks)
  2. A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study (Noninterventional study on real-life effectiveness and health status)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Онбрез Бризхалер (FAQ)


Q: How quickly will I feel the effect after using Onbrez Breezhaler?

Studies and official information indicate that the airway-widening effect, known as bronchodilation, occurs rapidly. Clinical studies indicate that this effect is experienced rapidly, typically within a few minutes after the first dose is inhaled. The medication is designed to sustain this benefit continuously over 24 hours.


Q: Does Onbrez Breezhaler combine with common over-the-counter cold medicines?

Official regulatory documents do not specifically list every over-the-counter cold medicine interaction. However, caution is advised when using this drug with any medicine that may increase heart rate or blood pressure, as Onbrez Breezhaler itself can cause these effects. Information regarding combination use with specific cold medicines is best reviewed with a healthcare professional.


Q: Is there a risk of interaction with herbal supplements or teas?

According to the official product information, there are no specific warnings or mandatory time separations documented regarding interactions with general herbal products or teas. This means regulatory labeling does not identify a specific risk with general use, but it does not cover all possible supplements.


Q: What should I do if I accidentally inhale the powder?

The capsule contains a powder that is specifically designed to be inhaled using the Breezhaler device. Inhaling the powder from the capsule is the intended method of administration. If there is uncertainty about the inhalation procedure, patients should follow the specific guidance provided in the official Instructions for Use to ensure the full dosage is received. The capsule is not intended to be swallowed.


Q: Why is the drug in the form of capsules for inhalation and not a spray?

The medication is supplied as an inhalation powder contained within hard capsules, which must be administered via the dedicated Breezhaler inhaler. This formulation uses a Dry Powder Inhaler (DPI) system. This method of delivery is the selected design choice for the active substance, Indacaterol, to ensure targeted and effective delivery directly into the airways.


Q: Can Onbrez Breezhaler be used if I don't have COPD?

According to official regulatory documents, the medication is indicated only for the long-term maintenance bronchodilator treatment of chronic obstructive pulmonary disease (COPD) in adults. It is not indicated for use in any other lung disease or condition, including using it to relieve acute, sudden breathing difficulties.


Q: How long do I need to take Onbrez Breezhaler before I can stop it?

Onbrez Breezhaler is designated for continuous, long-term maintenance treatment. The decision to stop treatment should be made only in consultation with a healthcare professional, as sudden discontinuation may lead to a worsening of the underlying symptoms of COPD.


Q: What is the Breezhaler device that comes with it for?

The Breezhaler device is a specialized inhaler designed to be the exclusive delivery system for the powdered medication. It contains a mechanism that punctures the capsule, allowing the user to inhale the dose effectively. Instructions for use describe specific cues that the device provides to help confirm the inhalation procedure.


Q: Can I drink coffee or alcohol when using Onbrez Breezhaler?

Official drug labels do not contain specific warnings regarding interactions with alcohol or coffee (caffeine). However, since the medication can increase heart rate and blood pressure, users should be aware that consuming large amounts of caffeine, which also has these effects, may potentially enhance them.


Q: Are there special instructions for people with liver or kidney problems?

Official regulatory guidance states that dose adjustment is generally not required for patients with mild or moderate impairment of kidney or liver function. However, the use of this drug in individuals with severe hepatic (liver) impairment has not been established, and safety information indicates limited data for this group.


Q: Can Onbrez Breezhaler be used if I am pregnant or breastfeeding?

Regulatory documents indicate that use during pregnancy is not recommended unless the anticipated benefit is determined by a physician to outweigh the potential risk to the fetus. Regarding breastfeeding, a decision is necessary to either discontinue nursing or discontinue the drug, taking into account the mother's need for the medication. The decision to use the drug is based on an individual assessment by a physician that the potential benefit outweighs the potential risk.


Q: Do studies indicate an improvement in quality of life with COPD?

Clinical studies have examined patient-reported outcomes, which include quality of life. Research using standardized assessment tools showed that findings indicated an association with statistically significant improvements in participants' symptom scores and their health-related quality of life compared to baseline measurements.


Q: Do I need to rinse my mouth after inhalation?

While some inhaled medications require a post-inhalation mouth rinse, this instruction is not universally mandatory for Onbrez Breezhaler in its official regulatory labeling as a monotherapy. Specific patient instructions, including any guidance on rinsing, are provided by the prescribing healthcare professional.


Q: How does Onbrez Breezhaler affect the ability to engage in physical activity?

The medication's mechanism is to maintain open airways, which may be associated with improved functional outcomes. Research has associated the use of this treatment with measured improvements in levels of daily physical activity, such as an increase in the average number of steps taken per day.


Q: What factors can influence the effectiveness of Onbrez Breezhaler?

Official information indicates that the medication's effectiveness relies primarily on strict adherence to the prescribed daily dosing schedule and correct technique when using the inhaler device. Additionally, taking certain drugs, such as beta-blockers, can reduce the intended bronchodilating effect of the medicine.


Q: What does "contraindications" mean in relation to Onbrez Breezhaler?

Contraindications are formally established conditions or circumstances, listed in official documents, under which the use of the medicine is strictly prohibited because the risks are considered unacceptably high. Examples include a known allergy to the drug components or using the drug for asthma treatment.


Q: How can I check if I am using the Breezhaler inhaler correctly?

The official Instructions for Use describe physical cues related to the device's function. During proper inhalation, you should hear a distinctive whirring or vibrating sound as the capsule spins inside the device. The official guidance states that the capsule should be empty after the inhalation is complete.


Q: In what cases might Onbrez Breezhaler not work?

The medicine is strictly for long-term maintenance treatment and will not relieve acute, sudden breathing problems, which is one condition where it might appear to 'not work.' Its effect may also be diminished by co-administering certain incompatible medicines, such as beta-adrenergic blockers, or if the patient's underlying disease rapidly worsens.


Q: Could there be a problem if I forget to take it several days?

As a maintenance treatment, the drug requires continuous use to sustain its beneficial effect on the airways. Discontinuation of the drug should be discussed with a healthcare provider, as missing the daily dose for multiple days can lead to a reduction in therapeutic benefit and a potential worsening of COPD symptoms.

Advertisements

How should Онбрез Бризхалер be stored and disposed of?

Official Storage Requirements

Onbrez Breezhaler must be stored at a temperature that does not exceed 30^circmathrmC. The medicine should be kept in a cool, dry place, away from excessive heat and direct sunlight. It is mandatory that the capsules always remain in the original blister pack until the moment of administration to protect them from moisture and light. Capsules must be removed from the blister immediately before use and must not be stored inside the inhaler device.

Inhaler Lifespan and Disposal

The accompanying Breezhaler inhaler device has a defined lifespan and must be disposed of after 30 days of use or once all capsules provided in the pack have been administered. To ensure environmental protection, unused or expired medicine and the used inhaler must not be thrown away via wastewater or regular household waste. Patients should consult a pharmacist for guidance on the proper disposal of unused medicinal products. As a general precaution, the medicine must be stored out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Онбрез Бризхалер found in:

A-Z Index: